Organogenesis Holdings Inc (ORGO) Stock Price, Quote & News

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 575 0775

Website: organogenesis.com

Address:

85 Dan Road, Canton, United States

meowmeow5 Nov. 14 at 2:57 PM

$ORGO $10 by dec?

2 · Reply

StockScanners Nov. 13 at 3:24 AM

$ORGO reached 7.08

0 · Reply

meowmeow5 Nov. 12 at 5:05 PM

$ORGO powder keg

0 · Reply

Mobagri Nov. 12 at 4:40 PM

$ORGO bright future ahead with little if any competition in skin grafts. More catalysts coming. $8 stock price is way overdue

0 · Reply

healthcareguru Nov. 12 at 3:28 PM

$ORGO insanely overbought after squeeze…now back to the gutter <$5. 👎

0 · Reply

Mobagri Nov. 12 at 2:40 PM

$ORGO take advantage of the dip and buy

0 · Reply

isaacwilliams33 Nov. 11 at 8:44 PM

$GIFI $ORGO $IXHL $GTBP

0 · Reply

Mobagri Nov. 11 at 3:36 PM

$ORGO I’d say around December 12 th

0 · Reply

Mobagri Nov. 11 at 3:20 PM

$ORGO this Mimedyx troll is vanished like pee on a rock.

0 · Reply

Mobagri Nov. 11 at 3:16 PM

$ORGO this stock is non stop go up. Keep buying non stop

0 · Reply

Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 8 days ago

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Nov 3, 2025, 1:10 PM EST - 12 days ago

Organogenesis Applauds CMS's Significant Step In Payment Reform

Oct 31, 2025, 4:05 PM EDT - 14 days ago

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 17, 2025, 2:20 PM EDT - 4 weeks ago

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

Oct 1, 2025, 4:05 PM EDT - 6 weeks ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Sep 29, 2025, 8:26 AM EDT - 6 weeks ago

Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish

Sep 26, 2025, 11:24 AM EDT - 7 weeks ago

Why Is Organogenesis Stock Trading Lower Friday?

Sep 25, 2025, 4:50 PM EDT - 7 weeks ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Aug 8, 2025, 6:30 PM EDT - 3 months ago

Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:05 PM EDT - 4 months ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Jul 15, 2025, 9:00 AM EDT - 4 months ago

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Jun 9, 2025, 5:39 PM EDT - 5 months ago

Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

May 11, 2025, 10:14 AM EDT - 6 months ago

Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Apr 11, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Apr 7, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Feb 27, 2025, 8:27 PM EST - 9 months ago

Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Jan 27, 2025, 7:30 AM EST - 10 months ago

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Nov 22, 2024, 4:05 PM EST - 1 year ago

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Nov 15, 2024, 9:25 AM EST - 1 year ago

Organogenesis Commends Final LCDs

Nov 12, 2024, 11:02 PM EST - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Nov 11, 2024, 5:05 PM EST - 1 year ago

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Aug 8, 2024, 11:08 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

May 9, 2024, 9:01 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Feb 29, 2024, 11:06 PM EST - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Feb 12, 2024, 7:30 AM EST - 1 year ago

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb 8, 2024, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Nov 9, 2023, 10:16 PM EST - 2 years ago

Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Oct 5, 2023, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Sep 28, 2023, 9:15 AM EDT - 2 years ago

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Jul 20, 2023, 11:31 AM EDT - 2 years ago

Organogenesis: Solid Revenue Generation From A Hyper-Trading Wound Care Company

meowmeow5 Nov. 14 at 2:57 PM

$ORGO $10 by dec?

2 · Reply

StockScanners Nov. 13 at 3:24 AM

$ORGO reached 7.08

0 · Reply

meowmeow5 Nov. 12 at 5:05 PM

$ORGO powder keg

0 · Reply

Mobagri Nov. 12 at 4:40 PM

$ORGO bright future ahead with little if any competition in skin grafts. More catalysts coming. $8 stock price is way overdue

0 · Reply

healthcareguru Nov. 12 at 3:28 PM

$ORGO insanely overbought after squeeze…now back to the gutter <$5. 👎

0 · Reply

Mobagri Nov. 12 at 2:40 PM

$ORGO take advantage of the dip and buy

0 · Reply

isaacwilliams33 Nov. 11 at 8:44 PM

$GIFI $ORGO $IXHL $GTBP

0 · Reply

Mobagri Nov. 11 at 3:36 PM

$ORGO I’d say around December 12 th

0 · Reply

Mobagri Nov. 11 at 3:20 PM

$ORGO this Mimedyx troll is vanished like pee on a rock.

0 · Reply

Mobagri Nov. 11 at 3:16 PM

$ORGO this stock is non stop go up. Keep buying non stop

0 · Reply

TQQQQ Nov. 11 at 3:01 PM

$ORGO hot buy

0 · Reply

dbr_island Nov. 11 at 2:54 PM

$ORGO there it goes.. Now calling 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

0 · Reply

eyeownu Nov. 11 at 2:44 PM

$ORGO doing it big today huh

0 · Reply

meowmeow5 Nov. 11 at 2:19 PM

$ORGO I work in this field. Lots of interest in this company!

0 · Reply

CrytpoConverter Nov. 11 at 12:02 PM

$ORGO I bought this at $2.75, looks like 8 is about where this could end up maybe a spike to 10 and then end up around 9 then bleed down.. 🤔 thoughts?

0 · Reply

SadyK189 Nov. 11 at 4:17 AM

Top Stocks to watch tomorrow 2 / 2: $BW $OPEN $SKYT $ORGO $AIIO BW: Initially alerted at 2.47. Kept posting about it. Still looking good on daily chart. Key support at 5.30 - 5.70 now. Next key level to test lies at 7.80 - 8.20. Currently at 7.13 OPEN: Getting up on 4hours chart. Key support at 6.65 - 7.05. Next key level to test is 8.90 - 9.15. Currently at 8.33 SKYT: Good close of daily candle. 20.3 - 21 is acting as key support zone. Next key level to test is 25.40 - 25.90 Currently at 23.90. ORGO: Looking good on daily chart. Key support at 5.2 - 5.60. Next key level to test is 7.45 - 7.70. Currently at 6.60 AIIO: Getting up on 4hours chart. Key support at 0.54 - 0.58. Next key level to test is 0.77 - 0.81. Currently at 0.68

0 · Reply

GORILLATRADERR Nov. 11 at 3:40 AM

$ORGO SS:6.03 BC:6.13 Loss.10

0 · Reply

jacksparo Nov. 11 at 12:19 AM

$ORGO Added between may to June it was below 3 bucks based on my plan. Up good in it.

1 · Reply

Zackpedia Nov. 10 at 11:48 PM

$ORGO Selling time above 6.58

0 · Reply

ppl_first Nov. 10 at 8:44 PM

$ORGO Probably another huge mistake but I'm in at the top, 6.46.

1 · Reply

Mobagri Nov. 10 at 8:05 PM

$ORGO once they submit BLA for Renu and Clinical results to CMS on PuraPly they rule the wound care space. Next year around this time I predict $16

0 · Reply

fanninac89 Nov. 10 at 8:04 PM

$ORGO ... Going up very well. I'll be holding this one.

0 · Reply

Market Cap	788.12M
Revenue (ttm)	482.04M
Net Income (ttm)	860,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	81.00
Profit Margin	0.18%
Debt to Equity Ratio	0.00

Volume	1,160,000
Avg Vol	1,560,512
Day's Range	N/A - N/A
Shares Out	126.91M
Stochastic %K	70%
Beta	1.68
Analysts	Strong Sell
Price Target	$7.50